<?xml version="1.0" encoding="UTF-8"?>
<p id="p0345">Among the compounds listed in 
 <xref rid="appsec1" ref-type="sec">Table S1, 19</xref> are already included in the clinical trials database, 
 <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0055" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link>, for their exploitation as antiviral compounds (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" id="intref0060" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/</ext-link>) (
 <xref rid="appsec1" ref-type="sec">Table S1</xref>). Among these, only the tannic acid, the curcumin and the aescin have been selected to undergo clinical trials for testing their efficacy in patients affected by human coronaviruses. In particular, they are all being tested for their efficacy against SARS-CoV2. In the randomized controlled trial on tannin specific natural extract (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04403646?term=Tannic+acid&amp;cond=Coronavirus+Infection&amp;draw=2&amp;rank=1" id="intref0065" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04403646</ext-link>), the molecular complex ARBOX, composed by quebracho, Vit B12 and chestnut tannins extracts, is being tested as a dietary supplement in patient infected by SARS-CoV2 in addition to the conventional standard therapy (including antipyretics or lopinavir/ritonavir, azithromycin and hydroxychloroquine).
</p>
